ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0698

Differentiating Large Vessel Vasculitis from Vasculitis Mimickers in a Real World Setting: Clinical Presentation, Laboratory Tests and Radiographic Findings

James haigney1, Laura Fandino1 and Vasileios Kyttaris2, 1Beth Israel Deaconess Medical Center, Boston, MA, 2BIDMC, Boston, MA

Meeting: ACR Convergence 2023

Keywords: Imaging, radiography, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0691–0721) Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: As the resolution of Computed Tomography Angiography (CTA) has improved, rheumatologists have faced an increased volume of consults to evaluate patients for the presence of radiographic abdominal vasculitis (RAV). Biopsy is often not possible due to the nature of the lesion. In our experience, a large portion of these patients are ultimately not found to have vasculitis after a thorough evaluation. In this study we sought to identify the most predictive symptoms, laboratory, and imaging findings of having RAV at the first point of contact with the rheumatology consult service.

Methods: Patients with billing codes for vasculitis or non-inflammatory arteriopathies (NIA) evaluated by the rheumatology service between January 1, 2016 and December 31, 2021 were considered for inclusion in this study. Of these, only patients with question of vasculitis by imaging of the renal arteries, abdominal aorta, or mesenteric arteries and their branches (celiac, inferior and superior mesenteric arteries) with >1 year of follow up were included in the final analysis. Biographic data, presenting symptoms, laboratory data, and imaging reports were extracted. Patients were classified by their final diagnosis at the 1-year time point as either having vasculitis or NIA as determined by the treating physician based on their clinical course and response to treatment. Statistical analysis was conducted using STATA software.

Results: Of 683 candidate patients, 63 were seen by rheumatology for the question of RAV. 27 were excluded for insufficient data, 1 was excluded for question of vasculitis surrounding a stent, and 35 were included in the final analysis. Of these, 17 were ultimately determined to have vasculitis, and 18 were determined to not have vasculitis. Baseline patient characteristics are available in table 1. Notably 2 patients ultimately found to not have vasculitis received treatment for vasculitis in the follow up period, and 1 patient ultimately found to have vasculitis was managed as non-vasculitis with observation before treatment was initiated. Analysis of the predictive value of imaging findings and presenting symptoms are reported in table 2. Notably, wall thickening of the relevant vessels was found to be the most helpful finding with a specificity of 83% and positive likelihood ratio (+LR) of 3.53. Interestingly fat stranding was found to be less helpful with a specificity of 67% and +LR of 1.2. Wall enhancement was rarely seen but was highly specific for vasculitis with a specificity of 94% and +LR of 3.18. None of the presenting symptoms were found to be especially predictive of vasculitis. Analysis of laboratory findings on presentation revealed initial white blood cell count (WBC) and platelet count (Plt) were significantly higher in patients with vasculitis (Table 3).

Conclusion: Our study identified wall thickening, wall enhancement, and elevations in WBC and Plt as being predictive of having abdominal vasculitis. While commonly reported, fat stranding was non-specific. Interestingly the tested presenting symptoms were not successful in delineating which patients were ultimately determined to have vasculitis. Confirmation of these findings with larger prospective studies is warranted.

Supporting image 1

Table 1: Demographics and clinical characteristics of patients at baseline diagnosed with vasculitis vs non-vasculitis after consultation for question of RAV. AID denotes autoimmune disease, HTN smoking, HLD hyperlipidemia, and CAD coronary artery disease.

Supporting image 2

Table 2: Sensitivity, specificity, and positive/negative likelihood ratios (+LR/-LR) of presenting symptoms and CTA findings of patients with and without vasculitis.

Supporting image 3

Table 3: Comparison of baseline laboratory values (P < 0.05 is statistically significant). CRP denotes C-reactive protein, WBC white blood cell count, Plt platelets, AST aspartate aminotransferase, ALT alanine aminotransferase, ALP alkaline phosphatase, and IQR interquartile range. CRP is in mg/L. AST, ALT, and ALP are in mg/dL. WBC and Plt are in K/µL.


Disclosures: J. haigney: None; L. Fandino: None; V. Kyttaris: AbbVie/Abbott, 5, AstraZeneca, 2, Aurinia, 1, EMD Serono, 5, Exagen, 2, 5, Fresenius Kabi, 1, Horizon Pharmaceuticals, 1, Novartis, 5, Scipher, 1, Takeda, 5, Vertex, 2.

To cite this abstract in AMA style:

haigney J, Fandino L, Kyttaris V. Differentiating Large Vessel Vasculitis from Vasculitis Mimickers in a Real World Setting: Clinical Presentation, Laboratory Tests and Radiographic Findings [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/differentiating-large-vessel-vasculitis-from-vasculitis-mimickers-in-a-real-world-setting-clinical-presentation-laboratory-tests-and-radiographic-findings/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/differentiating-large-vessel-vasculitis-from-vasculitis-mimickers-in-a-real-world-setting-clinical-presentation-laboratory-tests-and-radiographic-findings/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology